Literature DB >> 22692290

Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.

Rajal B Shah1, Ming Zhou.   

Abstract

Atypical cribriform lesions of the prostate gland consist of cribriform and rarely solid proliferation of prostate glands populated with cytologically atypical cells with partial or complete basal cell lining. It may represent cribriform "high-grade prostatic intraepithelial neoplasia" (HGPIN) or "intraductal carcinoma of the prostate" (IDC-P). IDC-P is almost always associated with clinically aggressive and high-volume prostate carcinoma. In contrast, cribriform HGPIN is a putative neoplastic precursor lesion, and recent data have questioned whether HGPIN on needle biopsy is associated with a significantly increased cancer risk in subsequent biopsies, and whether the diagnosis mandates rebiopsy within the first year after its diagnosis. As the result, the distinction between these 2 lesions has profound clinical implications, especially on needle biopsies. Since its original description, several studies have attempted to further refine histologic definition of IDC-P in the past decade. Even though presence of certain morphologic features (eg, pleomorphic nuclei or nuclei 6× the size of adjacent nuclei, intraluminal necrosis, and dense cribriform and solid architecture) are seen only in IDC-P, IDC-P may also exhibit "low-grade" morphologic features that overlap with cribriform HGPIN. Emerging molecular data on TMPRSS:ERG gene fusions further support the fact that these 2 lesions are biologically distinct. IDC-P is an uncommon finding in prostate biopsies; however, patients with IDC-P as sole findings without concomitant prostate carcinoma in biopsy are recommended for either definitive treatment or immediate repeat biopsy. This article summarizes the morphologic and molecular characteristics of IDC-P and cribriform HGPIN and an approach to work-up of atypical cribriform lesions in prostate needle biopsies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692290     DOI: 10.1097/PAP.0b013e31825c6c0e

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  8 in total

1.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.

Authors:  Kosuke Miyai; Mukul K Divatia; Steven S Shen; Brian J Miles; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 2.  Intraductal carcinoma of prostate (IDC-P): from obscure to significant.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 3.  Intraductal carcinoma of prostate: a comprehensive and concise review.

Authors:  Jordan A Roberts; Ming Zhou; Yong Wook Park; Yong Wok Park; Jae Y Ro
Journal:  Korean J Pathol       Date:  2013-08-26

Review 4.  [Intraductal carcinoma of the prostate].

Authors:  G Kristiansen; M Varma; G Seitz
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

5.  Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.

Authors:  Carlos L Morais; Jeong S Han; Jennifer Gordetsky; Michael S Nagar; Ann E Anderson; Stephen Lee; Jessica L Hicks; Ming Zhou; Cristina Magi-Galluzzi; Rajal B Shah; Jonathan I Epstein; Angelo M De Marzo; Tamara L Lotan
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

6.  Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Authors:  Michael C Haffner; Christopher Weier; Meng Meng Xu; Ajay Vaghasia; Bora Gürel; Berrak Gümüşkaya; David M Esopi; Helen Fedor; Hsueh-Li Tan; Ibrahim Kulac; Jessica Hicks; William B Isaacs; Tamara L Lotan; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  J Pathol       Date:  2015-10-14       Impact factor: 7.996

7.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

Review 8.  Intraductal carcinoma of the prostate.

Authors:  Eszter Szentirmai; Giovanna Angela Giannico
Journal:  Pathologica       Date:  2020-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.